TY  - JOUR
AU  - Grande, Enrique
AU  - Teulé, Alex
AU  - Alonso-Gordoa, Teresa
AU  - Jiménez-Fonseca, Paula
AU  - Benavent, Marta
AU  - Capdevila, Jaume
AU  - Custodio, Ana
AU  - Vera, Ruth
AU  - Munarriz, Javier
AU  - La Casta, Adelaida
AU  - Díez, Juan José
AU  - Gajate, Pablo
AU  - Molina-Cerrillo, Javier
AU  - Matos, Ignacio
AU  - Cristóbal, Eva María
AU  - Ruffinelli, José C
AU  - Palacios, José
AU  - García-Carbonero, Rocío
PY  - 2020
DO  - 10.1634/theoncologist.2020-0033
UR  - http://hdl.handle.net/10668/15086
T2  - The oncologist
AB  - Palbociclib demonstrated no detectable activity in molecularly unselected and heavily pretreated patients with advanced grade 1/2 pancreatic neuroendocrine tumors. Predictive biomarkers that improve patient selection should be investigated in future...
LA  - en
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Female
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Neuroendocrine Tumors
KW  - Pancreatic Neoplasms
KW  - Piperazines
KW  - Pyridines
KW  - Spain
TI  - The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407).
TY  - research article
VL  - 25
ER  -